Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 7/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.38 |
| ▸ | MMP3 | P08254 | 2/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3638571 | 0.81 | LDHA (0.46) | RENMMP1MMP13LDHAPPARG | |
| SCHEMBL11443642 | 0.81 | REN (0.47) | RENMMP13ACACBAAK1 | |
| SCHEMBL3776724 | 0.80 | LDHA (0.54) | RENMMP13LDHAPPARGPPARA | |
| SCHEMBL6942693 | 0.80 | LDHA (0.54) | RENMMP13LDHAPPARGPPARA | |
| SCHEMBL3777215 | 0.79 | LDHA (0.46) | MMP13LDHAAAK1ALDH1A1 | |
| SCHEMBL11116045 | 0.74 | REN (0.47) | REN | |
| SCHEMBL15223320 | 0.74 | REN (0.41) | RENLDHAAAK1ALDH1A1 | |
| SCHEMBL22275832 | 0.73 | MMP1 (0.43) | RENMMP1MMP3MMP9ALDH1A1 | |
| SCHEMBL6321168 | 0.73 | CTSS (0.46) | RENMMP13AAK1MMP3 | |
| SCHEMBL24443461 | 0.73 | MAPT (0.49) | RENMMP13LDHAPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170218025-A1 | BOUVARDIN DERIVATIVES AND THERAPEUTIC USES THEREOF | SUVICA, INC. | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170218025-A1 | BOUVARDIN DERIVATIVES AND THERAPEUTIC USES THEREOF | EIF4E, EIF4EBP1, RPL30 | REN 758/4885MMP1 4343/4885MMP13 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.